Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding Ltd
(OP:
RHHVF
)
336.07
+1.64 (+0.49%)
Streaming Delayed Price
Updated: 2:46 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding Ltd
< Previous
1
2
3
4
5
6
7
Next >
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
February 18, 2022
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab...
Via
Benzinga
Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests
February 03, 2022
Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH
Via
Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
February 02, 2022
Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,
Via
Benzinga
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
February 01, 2022
Biogen Inc (NASDAQ: BIIB) has
Via
Benzinga
FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo
January 31, 2022
The FDA has approved Genentech's, a unit of
Via
Benzinga
Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months
January 25, 2022
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (...
Via
Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
January 12, 2022
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild...
Via
Benzinga
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
December 20, 2021
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)...
Via
Benzinga
Novartis Launches New Share Buyback Program Of Up To $15B
December 16, 2021
Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth...
Via
Benzinga
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
December 15, 2021
Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape...
Via
Benzinga
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
December 14, 2021
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen...
Via
Benzinga
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
December 13, 2021
Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60%...
Via
Benzinga
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
December 10, 2021
Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS)....
Via
Benzinga
Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer
December 10, 2021
Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus...
Via
Benzinga
Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19
December 07, 2021
The European Commission has extended the marketing authorization for Roche Holdings AG's (OTC: RHHBY) Actemra/RoActemra (Tocilizumab) to treat patients with severe...
Via
Benzinga
Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients
December 06, 2021
Immunocore Holdings Plc (NASDAQ: IMCR) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid...
Via
Benzinga
Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests
December 03, 2021
President Biden announced that private health insurance plans would soon reimburse people who buy over-the-counter (OTC), at-home rapid tests for COVID-19. What Happened...
Via
Benzinga
Exposures
COVID-19
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
December 02, 2021
Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY...
Via
Benzinga
Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer
November 19, 2021
The European Commission (EC) has granted conditional marketing authorization to Roche Holdings AG's (OTC: RHHBY) Gavreto (pralsetinib) for treating adults...
Via
Benzinga
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes
November 18, 2021
Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced data from its Phase 1/2 trial of SPK-8011 in hemophilia A. At a median efficacy follow-up of 33.4...
Via
Benzinga
Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill
November 17, 2021
Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month...
Via
Benzinga
Exposures
COVID-19
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail
November 12, 2021
The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and...
Via
Benzinga
Exposures
COVID-19
EU Regulator Backs Regeneron-Roche's COVID-19 Drug
November 11, 2021
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc...
Via
Benzinga
Exposures
COVID-19
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
November 10, 2021
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition....
Via
Benzinga
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
November 09, 2021
ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/...
Via
Benzinga
Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose
November 08, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg...
Via
Benzinga
Exposures
COVID-19
Novartis To Offload Its Stake Back To Roche For $20.7B
November 04, 2021
Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting...
Via
Benzinga
Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting
November 02, 2021
Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in...
Via
Benzinga
Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics
October 20, 2021
Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.